从资金流向上来看，当日软件开发板块主力资金净流出7.19亿元，游资资金净流入2.17亿元，散户资金 净流入5.02亿元。软件开发板块个股资金流向见下表： 证券之星消息，12月10日软件开发板块较上一交易日上涨0.21%，*ST国华领涨。当日上证指数报收于 3900.5，下跌0.23%。深证成指报收于13316.42，上涨0.29%。软件开发板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Group 1 - The Shanghai Composite Index closed at 3900.50 points, slightly down by 0.23%, with a total trading volume of 1,791.634 billion yuan [1] - A total of 57 A-shares have surpassed their annual line, with notable stocks showing significant deviation rates including Huaxi Co., Huaxia Happiness, and Haide Co. at 9.52%, 9.41%, and 6.86% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Zhongtong Bus, Xusheng Group, and Hongyuan Electronics [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Huaxi Co. (10.07% increase, 7.98 yuan latest price, 9.52% deviation) - Huaxia Happiness (9.92% increase, 2.66 yuan latest price, 9.41% deviation) - Haide Co. (9.98% increase, 6.94 yuan latest price, 6.86% deviation) [1] - Other notable stocks with significant increases include *ST Guohua (5.01% increase), Huajin Capital (10.01% increase), and Zhongbai Group (9.97% increase) [1] - The trading turnover rates for these stocks vary, with Huaxi Co. at 7.82%, Huaxia Happiness at 13.49%, and Haide Co. at 3.67% [1] Group 3 - Additional stocks that have recently crossed the annual line with lower deviation rates include: - Yujian Intelligent (10.00% increase, 15.95 yuan latest price, 2.46% deviation) - Baiyang Pharmaceutical (4.50% increase, 23.44 yuan latest price, 2.37% deviation) - Meikailong (10.04% increase, 3.07 yuan latest price, 1.94% deviation) [1] - The overall market sentiment appears stable with a slight decline in the index, indicating potential opportunities for investors focusing on stocks with strong performance above the annual line [1]

证券代码：000004 证券简称：*ST 国华 公告编号：2025-089 深 圳 国 华 网 安 科 技 股 份 有 限 公 司 关于重大诉讼的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：二审已作出判决 2、上市公司所处的当事人地位：原告，反诉被告，被上诉人 3、涉案的金额：12,734,198.73 元 4、对上市公司损益产生的影响：本案二审判决维持原判，公司将依据有关会计准则的 要求和案件后续进展情况进行相应的会计处理，具体影响以公司后续财务核算结果为准。 一、 本次重大诉讼的基本情况 深圳国华网安科技股份有限公司（以下称"上市公司"或"公司"）控股子公 司深圳智游网安科技有限公司（以下简称"深圳智游"）因买卖合同纠纷向广东 省深圳市福田区人民法院（以下简称"福田法院"）提起诉讼，请求判决被告支 付相关采购订单尚欠货款及逾期付款违约金，并承担诉讼费、保全费，案号为（2025） 粤 0304 民初 29119 号，具体内容详见公司于 2025 年 5 月 6 日披露的《关于重大诉 讼的公告》（公告编号：20 ...

Investment Overview - Shenzhen Guohua Network Security Technology Co., Ltd. approved a capital increase of 1.04 million RMB to Zhongshan Runle Pharmaceutical Co., Ltd. through its subsidiary, Shenzhen Guoke Zhijian Pharmaceutical Co., Ltd. [1] - The decision was made during the 12th Board of Directors meeting on December 1, 2025, and further details were disclosed on December 2, 2025 [1]. Progress of Investment - As of the announcement date, Runle Pharmaceutical has completed the registration change and received a new business license from the Zhongshan Market Supervision Administration [2]. - The registered capital of Runle Pharmaceutical has increased to 2.04 million RMB, with Guoke Zhijian holding 50.9804% of the shares, thus consolidating Runle Pharmaceutical into the company's financial statements [2]. Company Information - Company Name: Zhongshan Runle Pharmaceutical Co., Ltd. [4] - Unified Social Credit Code: 91440112MAE9DGMY39 [4] - Legal Representative: Huang Xiang [4] - Company Type: Other limited liability company [4] - Establishment Date: January 27, 2025 [4] - Registered Capital: 2.04 million RMB [4] - Address: 4th Floor, No. 3 Building, Yongning Huaye Road, Xiaolan Town, Zhongshan City [4].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 一、对外投资概况 深圳国华网安科技股份有限公司（以下简称"公司"）于 2025 年 12 月 1 日 召开第十二届董事会 2025 年第九次临时会议，审议通过了《关于对中山润乐药 业有限公司增资的议案》，同意控股子公司深圳国科稚健医药有限公司（以下简 称"国科稚健"）以 104 万元对中山润乐药业有限公司（以下简称"润乐药业"） 进行增资，具体内容详见公司于 2025 年 12 月 2 日披露的《关于对中山润乐药业 有限公司增资的公告》（公告编号：2025-086）。 二、对外投资的进展情况 截至本公告披露日，润乐药业已就本次增资事宜办理了变更登记手续，并取 得了由中山市市场监督管理局换发的《营业执照》，具体信息如下： 1、公司名称：中山润乐药业有限公司 2、统一社会信用代码：91440112MAE9DGMY39 3、法定代表人：黄翔 4、公司类型：其他有限责任公司 5、成立日期：2025 年 01 月 27 日 6、注册资本：人民币贰佰零肆万元 7、住所：中山市小榄镇永宁华业路 25 号 3 号楼 4 楼 证券 ...

New Stock Listings - Jingchuang Electric (920035) listed at an issuance price of 12.10 on December 2, 2025[1] - Tianpu Co., Ltd. (605255) is in the offer period from November 20 to December 19, 2025[1] Market Alerts - ST Suwu (600200) enters the delisting arrangement period starting December 9, 2025[1] - Jianglong Shipbuilding (300589) reported severe abnormal fluctuations[1] Recent Announcements - Multiple companies including Beida Pharmaceutical (000788) and ST Green Health (002868) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities in the last week[2]

Group 1 - The company held its 9th temporary board meeting on December 1, 2025, to discuss and approve the capital increase in Zhongshan Runle Pharmaceutical Co., Ltd. [2][3] - The board unanimously approved the proposal for the capital increase, with all five attending directors voting in favor [3][4] - The capital increase involves an investment of 1.04 million RMB, which will result in the company holding 50.9804% of Runle Pharmaceutical's equity [8][11] Group 2 - Runle Pharmaceutical, established on January 27, 2025, has a registered capital of 1 million RMB and focuses on the sale of health food and pharmaceuticals, including a pediatric cough syrup recently granted market approval [8][9] - The capital increase will not constitute a major asset restructuring and does not require shareholder approval [8][15] - The funding for this investment will come from the company's own funds and will not affect its existing business operations [15] Group 3 - The company aims to expand its presence in the pharmaceutical sector through this investment, seeking to enhance its core competitiveness and create new revenue streams [15] - The future performance of Runle Pharmaceutical will be influenced by various factors, including policy, economic, and market conditions [15]

证券代码：000004 证券简称：*ST 国华 公告编号：2025-087 深 圳 国 华 网 安 科 技 股 份 有 限 公 司 股 票 交 易 异 常 波 动 公 告 针对上述情况，公司进行了必要核实，并对影响公司价格异常波动的事项说 明如下： 1、公司于 2025 年 8 月 23 日披露了《2025 年半年度报告》及《2025 年半年 度财务报告》，因部分内容录入有误，公司已进行更正，详见公司于 2025 年 8 月 27 日披露的《关于 2025 年半年度报告及财务报告更正的公告》（公告编号： 2025-063）。 2、公司未发现近期有公共传媒报道了可能或已经对公司股票交易价格产生 较大影响的未公开重大信息。 3、公司近期生产经营情况正常，内外部经营环境未发生重大变化。 4、公司近期筹划对中山润乐药业有限公司增资，并于 2025 年 12 月 1 日召 开董事会，审议通过了相关议案，详见公司同日披露的《第十二届董事会 2025 年第九次临时会议决议公告》（公告编号：2025-085）和《关于对中山润乐药业 有限公司增资的公告》（公告编号：2025-086）。除上述事项以外，公司、控股 股东和实际控制 ...

Core Viewpoint - *ST Guohua announced that its subsidiary, Shenzhen Guoke Zhijian Pharmaceutical Co., Ltd., has signed a capital increase agreement with Zhongshan Runle Pharmaceutical Co., Ltd., indicating a strategic investment to enhance its stake in the pharmaceutical sector [1] Group 1 - The company plans to invest 1.04 million yuan in Runle Pharmaceutical [1] - After the capital increase, Guoke Zhijian will hold 50.9804% equity in Runle Pharmaceutical [1] - Runle Pharmaceutical will be included in the company's consolidated financial statements following the completion of the investment [1]

Group 1 - The core point of the article is that *ST Guohua announced a temporary board meeting to discuss a capital increase for Zhongshan Runle Pharmaceutical Co., Ltd. [1] - For the first half of 2025, *ST Guohua's revenue composition is as follows: mobile network security accounts for 82.23%, pharmaceutical technology services for 12.49%, others for 3.65%, and emergency industry for 1.64% [1] - As of the report date, *ST Guohua has a market capitalization of 1.6 billion yuan [1]